ArticleFEBS open bio2026
Development of human monoclonal antibodies against TARM1 by yeast display.
Article in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
TARM1, a leukocyte immunoglobulin-like receptor expressed on myeloid cells, functions as a costimulatory receptor promoting proinflammatory cytokine secretion. Recent studies have revealed the involvement of TARM1 in immune-mediated diseases. Despite its biological importance, research tools for elucidating human TARM1 function have been limited. Here, we generated monoclonal antibodies (mAbs) against human TARM1 by a yeast display platform combined with a human single-chain variable fragment (scFv) library. Two scFv clones were isolated and converted into IgG1 antibodies, both of which bound recombinant TARM1 with high affinity and cell-surface TARM1. Importantly, these antibodies induced activation signals into Jurkat NFAT-GFP reporter cells expressing TARM1-CD28-4-1BB-CD3ζ chimera, indicating agonistic activity. These mAbs provide valuable tools for dissecting TARM1-mediated function and represent a potential approach for therapeutic strategies in inflammatory diseases and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.